Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles

Nicolas Borisov1, Anna Sergeeva2, Maria Suntsova3,4, Mikhail Raevskiy1, Nurshat Gaifullin5, Larisa Mendeleeva2, Alexander Gudkov3, Maria Nareiko2, Andrew Garazha6,7, Victor Tkachev6,7, Xinmin Li8, Maxim Sorokin3,6,7*, Vadim Surin2 and Anton Buzdin3,4,6*

1 Moscow Institute of Physics and Technology, Laboratory for Translational Genomic Bioinformatics, Dolgoprudny, Russia, 2 National Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia, 3 L.M. Sechenov First Moscow State Medical University, Institute of Personalized Medicine, Moscow, Russia, 4 Shemyakin-Ovchinnikov Institute of Biorganic Chemistry, Group for Genomic Analysis of Cell Signaling Systems, Moscow, Russia, 5 Department of Pathology, Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia, 6 Omicsway Corp., Research Department, Walnut, CA, United States, 7 Oncobox Ltd., Research Department, Moscow, Russia, 8 Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA, United States

Multiple myeloma (MM) affects ~500,000 people and results in ~100,000 deaths annually, being currently considered treatable but incurable. There are several MM chemotherapy treatment regimens, among which eleven include bortezomib, a proteasome-targeted drug. MM patients respond differently to bortezomib, and new prognostic biomarkers are needed to personalize treatments. However, there is a shortage of clinically annotated MM molecular data that could be used to establish novel molecular diagnostics. We report new RNA sequencing profiles for 53 MM patients annotated with responses on two similar chemotherapy regimens: bortezomib, doxorubicin, dexamethasone (PAD), and bortezomib, cyclophosphamide, dexamethasone (VCD), or with responses to their combinations. Fourteen patients received both PAD and VCD; six received only PAD, and 33 received only VCD. We compared profiles for the good and poor responders and found five genes commonly regulated here and in the previous datasets for other bortezomib regimens (all upregulated in the good responders): FGFR3, MAF, IGH2, IGHV1-69, and GRB14. Four of these genes are linked with known immunoglobulin locus rearrangements. We then used five machine learning (ML) methods to build a classifier distinguishing good and poor responders for two cohorts: PAD + VCD (53 patients), and separately VCD (47 patients). We showed that the application of FloWPS dynamic data trimming was beneficial for all ML methods tested in both cohorts, and also in the previous MM bortezomib datasets. However, the ML models build for the different datasets did not allow cross-transferring, which can be due to different treatment regimens, experimental profiling methods, and MM heterogeneity.

Keywords: multiple myeloma, bortezomib, gene expression, machine learning, treatment response, fibroblast growth factor receptor 3, PAD, VCD

OPEN ACCESS

Edited by:
Jiayi Wang, Shanghai Jiaotong University, China
Reviewed by:
Yi Shi, Shanghai Jiaotong University, China
Xiao Zhang, Shanghai Jiaotong University, China
*Correspondence:
Anton Buzdin
buzdin@oncobox.com

Specialty section:
This article was submitted to Cancer Genetics, a section of the journal Frontiers in Oncology
Received: 11 January 2021
Accepted: 19 March 2021
Published: 15 April 2021

Citation:
Borisov N, Sergeeva A, Suntsova M, Raevskiy M, Gaifullin N, Mendeleeva L, Gudkov A, Nareiko M, Garazha A, Tkachev V, Li X, Sorokin M, Surn V and Buzdin A (2021) Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles. Front. Oncol. 11:652063. doi: 10.3389/fonc.2021.652063

Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles

Nicolas Borisov1, Anna Sergeeva2, Maria Suntsova3,4, Mikhail Raevskiy1, Nurshat Gaifullin5, Larisa Mendeleeva2, Alexander Gudkov3, Maria Nareiko2, Andrew Garazha6,7, Victor Tkachev6,7, Xinmin Li8, Maxim Sorokin3,6,7*, Vadim Surin2 and Anton Buzdin3,4,6*

1 Moscow Institute of Physics and Technology, Laboratory for Translational Genomic Bioinformatics, Dolgoprudny, Russia, 2 National Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia, 3 L.M. Sechenov First Moscow State Medical University, Institute of Personalized Medicine, Moscow, Russia, 4 Shemyakin-Ovchinnikov Institute of Biorganic Chemistry, Group for Genomic Analysis of Cell Signaling Systems, Moscow, Russia, 5 Department of Pathology, Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia, 6 Omicsway Corp., Research Department, Walnut, CA, United States, 7 Oncobox Ltd., Research Department, Moscow, Russia, 8 Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA, United States

Multiple myeloma (MM) affects ~500,000 people and results in ~100,000 deaths annually, being currently considered treatable but incurable. There are several MM chemotherapy treatment regimens, among which eleven include bortezomib, a proteasome-targeted drug. MM patients respond differently to bortezomib, and new prognostic biomarkers are needed to personalize treatments. However, there is a shortage of clinically annotated MM molecular data that could be used to establish novel molecular diagnostics. We report new RNA sequencing profiles for 53 MM patients annotated with responses on two similar chemotherapy regimens: bortezomib, doxorubicin, dexamethasone (PAD), and bortezomib, cyclophosphamide, dexamethasone (VCD), or with responses to their combinations. Fourteen patients received both PAD and VCD; six received only PAD, and 33 received only VCD. We compared profiles for the good and poor responders and found five genes commonly regulated here and in the previous datasets for other bortezomib regimens (all upregulated in the good responders): FGFR3, MAF, IGH2, IGHV1-69, and GRB14. Four of these genes are linked with known immunoglobulin locus rearrangements. We then used five machine learning (ML) methods to build a classifier distinguishing good and poor responders for two cohorts: PAD + VCD (53 patients), and separately VCD (47 patients). We showed that the application of FloWPS dynamic data trimming was beneficial for all ML methods tested in both cohorts, and also in the previous MM bortezomib datasets. However, the ML models build for the different datasets did not allow cross-transferring, which can be due to different treatment regimens, experimental profiling methods, and MM heterogeneity.

Keywords: multiple myeloma, bortezomib, gene expression, machine learning, treatment response, fibroblast growth factor receptor 3, PAD, VCD
INTRODUCTION

Multiple myeloma (MM) is a hematological cancer which arises from abnormal antibody producing white blood plasma cells (1). MM affects approximately 500,000 people and results in ~100,000 deaths annually (2, 3) being currently considered treatable but rarely curable (4, 5). There are several MM chemotherapy treatment regimens currently in use, among which eleven include bortezomib (6) (Table 1). Bortezomib is a targeted drug that specifically binds and inhibits 26S proteasome, thus affecting proteolytic degradation pathways (20). Patients with MM respond differently on bortezomib-containing treatment schemes (21), and many patients develop adverse effects including neuromuscular and cardiovascular toxicity (22). Thus, new prognostic biomarkers are needed to personalize treatments with bortezomib (21).

High-throughput gene expression data including RNA sequencing profiles can be used for finding effective cancer biomarkers (23, 24). There is a shortage now for clinically annotated molecular profiles of MM that could be used to establish novel molecular diagnostics for most of the current clinical treatment regimens. For several regimens with bortezomib, MM gene expression profiles had been previously established and published for patients who were classified as either responders or non-responders. For example, in a study (25) using Affymetrix Human Genome U133 expression microarrays, 169 MM profiles were published for 85 responder patients and for 84 non-responders on monotherapy with bortezomib (26). In another paper (27) an Affymetrix Human Exon 1.0 ST Array expression dataset was published with the 33 files had been previously annotated with the documented responses on two chemotherapy treatments and subjected to RNA sequencing. Following treatment, the patients were clinically observed and reagents as for the ANTE database of RNA sequencing profiles for healthy human tissues and are, therefore, fully compatible with the enclosed eleven profiles for the normal CD138+ cells (47).

The MM biosamples investigated here were taken prior to the first-line chemotherapy treatments and subjected to RNA sequencing. Following treatment, the patients were clinically characterized to assess clinical responses according to the International Myeloma Working Group. Totally, 11 high-quality profiles were obtained for the “complete responders” (CR), 17 for “very good partial responders” (VGPR), and 56 for “minimal responders” (MR), where CR + VGPR can be considered good responders and PR + MR—poor responders. Among them, 14 patients received both PAD and VCD treatments (3–12 courses, sequentially), 33 received only VCD (3–12 courses) and 6—only PAD (4–6 courses).

We then used enhanced algorithms for five machine learning (ML) methods to build a classifier distinguishing good and poor treatment responders: support vector machines (SVM), Tikhonov (ridge) regression (RR), binomial naïve Bayes (BNB),...
random forest (RF) and multi-layer perceptron (MLP). The best result for full PAD+VCD cohort (n = 53) was produced by BNB method (AUC 0.84, sensitivity >0.8, specificity >0.84), and for the VCD cohort (n = 47) by the MLP method (AUC 0.89, sensitivity >0.87, specificity >0.83). In both optimal solutions, FloWPS dynamic data trimming method (26, 48, 49) was used to reduce data dimensionality. We also showed that the same approach was effective for classifying other annotated MM datasets with different bortezomib treatment regimens. We also compared gene expression profiles for the good and poor responders and found five genes commonly regulated here and in the previous datasets (all upregulated in the good responders): FGFR3, MAF, IGHA2, IGHV1-69, and GRB14.

MATERIALS AND METHODS

Clinically Annotated Biosamples

From March 2016 till June 2018, we collected 58 biosamples of bone marrow cells enriched for the presence of CD138-expressing mononuclear cells, isolated for the patients diagnosed with multiple myeloma (MM) and prescribed with further first-line chemotherapy treatments according to PAD and/or VCD regimens. The MM patients were 29–78 years old, mean age was 58 y.o., 31 male and 27 female patients (Supplementary Table 1). To isolate mononuclear cells, we used Ficoll Paque Plus medium (Sigma) according to the manufacturer’s recommendations. CD138+ cells fractions were obtained using magnetic granules coated with CD138-specific human antibodies MicroBeads (Miltenyi Biotec) and MS Columns (Miltenyi Biotec), according to the manufacturer’s recommendations. Cells were counted by Scepter™ 2.0 Handheld Automated Cell Counter (Merck Millipore) and immediately subjected to RNA extraction.

In parallel, a set of normal samples of CD138+ mononuclear cells was isolated from eleven 25–42 y.o. (mean age 32 y.o.; five males and six females) healthy volunteers as described in (47).

In all tumor related CD138+ experimental fractions the content of MM cells varied between 45 and 97%, as estimated by the pathologist using BD FACS Canto II flow cytometer (Becton Dickinson, USA) and phycoerythrin-conjugated anti-CD138 antibodies. This fraction was then subjected to RNA sequencing with approximately 30 million sequencing reads per library. In parallel, the patient treatment responses on bortezomib, doxorubicin, and dexamethasone (PAD) or bortezomib, cyclophosphamide, and dexamethasone (VCD) regimens, or their combinations, were registered and documented. Among them, 17 patients received both PAD and VCD treatments (3–12 courses, sequentially), 36 received only VCD (3–12 courses), and 5-only PAD (4–6 courses). Totally, 13 RNA sequencing profiles were obtained for the “complete responders” (CR), 17 for “very good partial responders” (VGPR), 14 for “partial responders” (PR), and 16 for “minimal responders” (MR), Supplementary Table 1. Moreover, for two poor responder cases (patients 111 and 115) we isolated MM mononuclear CD138+ cells following tumor relapse on PAD + VCD treatment and performed RNA sequencing (Supplementary Table 1).

For all the biosamples, informed written consents to participate in this study were collected from the patient’s legal representatives. The consent procedure and the design of the study were approved by the ethical committees of the Sechenov Moscow First Medical University, of the Clinical Center Vitamed (Moscow), and of the National Research Center for Hematology (Moscow, Russia).

Preparation of Libraries and RNA Sequencing

For RNA extraction, cells were resuspended in TRI Reagent (MRC) and then Direct-zol RNA MiniPrep (Zymo Research) was used for the RNA extraction. RNA was quantified using Nanodrop (Thermo Fisher Scientific), ethanol-precipitated, and stored in liquid nitrogen until sequencing. For library preparation, RNA Integrity Number (RIN) was measured using Agilent 2100 bioanalyzer. Agilent RNA 6000 Nano or Qubit RNA Assay Kits were used to measure RNA concentration. For depletion of ribosomal RNA, we used KAPA RNA Hyper with RiboErase Kit (KAPA Biosystems). Different adaptors were used for multiplexing samples in one sequencing run. Library concentrations and quality were measured using Qubit ds DNA HS Assay kit (Life Technologies) and Agilent Tapestation (Agilent). RNA sequencing was performed using Illumina HiSeq 3000 equipment for single end sequencing. 50 bp read length, for approximately 30 million raw reads per sample. Data quality check was conducted using Illumina SAV. De-multiplexing was performed using Illumina Bcl2fastq2 v 2.17 software. In parallel, we also isolated fractions of control CD138+ cells from eleven healthy volunteers and subjected them to RNA sequencing using the same protocol, equipment and reagents. The healthy donor profiles were published previously as part of the ANTE atlas of RNA sequencing data in healthy tissues (47).

Processing of RNA Sequencing Data

RNA sequencing FASTQ files were processed with STAR aligner (27) in ‘GeneCounts’ mode with the Ensembl human transcriptome annotation (Build version GRCh38 and transcript annotation GRCh38.89). Ensembl gene IDs were converted to HGNC gene symbols using Complete HGNC dataset (https://www.genenames.org, database version of July 13, 2017). In total, expression levels were established for 36,596 annotated genes with corresponding HGNC identifiers. Additional quality control (QC) metrics for obtained data were generated using NCBI MAGIC software (28, 49, 50). All metrics and detailed protocol for each sample can be found in Supplementary Table 2.

Data Clustering

‘1’ was added to all raw gene counts prior to cluster analyses, to avoid zero expression values, as described by Dillies et al. (51), the gene expression data were merged into single datasets and quantile normalized (52). Hierarchical clustering was performed using R ward.D2 method. The dendrogram was visualized using custom R script.
Dataset Preparation for Machine Learning (ML) Applications
According to (26, 48, 49), the preparation of datasets for the analysis included several steps: (i) normalization of expression levels using the DESeq2 method (51); (ii) finding top 30 marker genes having the highest AUC values for discriminating good and poor responder cases; (iii) performing the leave-one-out (LOO) cross-validation procedure to identify robust core marker gene set that will be used for building the ML models. The latter core marker gene set is an intersection of top 30 marker gene sets for all combinations of but one samples (26, 28, 48, 49).

ML Applications
Although modern ML applications in clinical cancer genomics may rely on deep learning methods (53–55), they require large preceding case cohorts (56), which was not the case for neither of the MM expression datasets under investigation. Thus, to further characterize them we used several non-deep ML methods implemented in the Python sklearn library (56).

The ML analysis of the experimental MM profiles was performed in two modes. First—when all 53 patients were included whose gene expression profiles passed the quality control (PAD+VCD cohort). Second, when 47 patients were included who had either only VCD or combination of PAD and VCD, but not only PAD (VCD cohort).

For each ML method we used a data trimming/preprocessing step using FlowPS method (R package flowpspkg.tar.gz) to increase robustness and efficiency due to individual sample-specific selection of training dataset (26, 48, 49). Among the ML methods, we used linear support vector machines (SVM) and ridge regression (RR) with default parameter settings for the sklearn package. Additionally, we applied random forest (RF), binomial naïve Bayes (BNB), and multi-layer perceptron (MLP) with the settings, which previously showed the best performance for building cancer responder classifiers (26). For RF these settings were n_estimators = 30, criterion = ‘entropy’. For BNB: alpha = 1.0, binarize = 0.0, and fit_prior = False. For MLP: hidden_layer_sizes = 30, alpha = 0.001. To compensate possible effect of unequal number of responder and non-responder samples, all SVM and RF calculations were done with setting class_weight = ‘balanced’ and class_weight = ‘balanced_subsample’, respectively. All other parameters were used with the default settings.

Data Records
MM gene expression profiles were deposited to Gene Expression Omnibus database (GEO) under accession number GSE159426. The data is provided as a matrix of raw counts as produced by STAR. The mapping statistic for the corresponding dataset is shown in Supplementary Table 2. The RNA sequencing profiles for healthy CD138-positive controls were deposited in GEO database with accession number GSE120795.

Code Availability
R code for building dendrograms with bar plots is freely available on Gitlab at: https://gitlab.com/borisov_oncobox/watermelon_multisection/blob/master/utils/gallow_plot.R. Flowpspkg.tar.gz is available on Gitlab at: https://gitlab.com/borisov_oncobox/flowpspkg.

RESULTS AND DISCUSSION
Initial Analysis of RNA Sequencing Data
Primary RNA sequencing data were characterized in detail with the NCBI MAGIC software (57) (Supplementary Table 2) and analyzed to assess if the profiles obtained are congruent with the biological nature of the biosamples under study. To this end we mixed the MM data obtained here with the profiles obtained by us using the same protocols, equipment and reagents for eleven samples of CD138+ cells of healthy volunteers (47). We performed hierarchical clustering analysis and observed that in line with the biological significance with one exception the norms formed a compact cluster on the dendrogram separately from the cancers (Figure 1). Furthermore, the outstanding normal profile had relatively low number of sequencing reads (Figure 1) and didn’t meet the previously established quality control (QC) criterion for this RNA sequencing protocol of having at least 2.5 million uniquely gene-mapped reads per library (47). This established threshold effectively marked samples with low quality values of other QC metrics, e.g. proportion of genomic counts, high rate of mismatches, number of reads spanning splice junction, high percentage of ribosomal counts (47). Filtering of the profiles that didn’t meet mapped-reads QC resulted in a tight clustering both on the dendrogram and on the principal component analysis (PCA) plot and removed healthy outlier (Figures 2A, B). However, the good (CR + VGPR) and poor (PR + MR) MM responders showed mixed trend and didn’t form any response-specific clusters (Figures 2C, D).

Building of ML-Assisted Classifiers for VCD MM Responders and Non-Responders
For our further analyses we used molecular profiles that passed mapped-reads QC and represented 53 MM patients (Supplementary Table 1), where 28 were classified as the good (CR + VGPR) and 25 as the poor (MR + PR) responders.

Reducing data dimensionality in disproportionately rich datasets is required for statistically justified tests (49). Prior to using machine learning (ML) approaches, we performed feature selection procedure to identify core marker gene expression set comparable in size to the number of the patient cases under analysis (26,28). To this end we selected the most informative fraction of the initial data that can distinguish between the good and poor treatment responder classes using a leave-one-out-based method (48). Because of the size of our MM dataset (n = 53 for full cohort and 47 for VCD) the n-fold cross-validation scheme is too rough for such a limited dataset, and the leave-one-out (i.e., 53/47-fold cross-validation approach for full/VCD cohort, respectively) is the best way to obtain more accurate results.

For each clinical case i = 1,…, 53/47, we determined the top 30 marker genes that distinguished responder and non-responder
cases in a sub-dataset that contains all samples but \( i \). For all 52/46 such sub-datasets each having 52/46 cases, we interrogated each gene taken one by one and obtained the set of top 30 genes showing the highest ROC AUC values for the difference between responder and non-responder profiles. Area under the ROC curve (AUC) is the universal metric of a biomarker robustness depending on its sensitivity and specificity (28). It varies from 0.5 till 1, and the standard discrimination threshold is typically set as 0.7, where the items with greater AUC are thought high-quality biomarkers (58). AUC is broadly used for scoring of molecular biomarkers in oncology (23, 59–62).

The final list of core marker genes was then obtained by intersecting top 30 gene sets for all 53/47 sub-datasets. By using this procedure, we obtained a set of 8 core marker genes whose expression was characteristic for the MM patient (non)responder cohort (Figures 3, 4; Table 2, Supplementary Tables 3, 4).

Interestingly, many of those genes were previously reported as cancer biomarkers. For example, gene **ARPC2** is prognostic biomarker in ovarian carcinomas (65). Gene **KLHDC7B** is regulated by interferon signaling pathway (66) and was previously published as the methylation marker in breast cancer (67) and also poor prognosis biomarker in triple negative breast cancer (68) and laryngeal cancer (69). **OSR2** gene is methylation marker in gastric cancer (70) and **TRIM9** was reported as cell-free DNA methylation marker of metastatic breast cancer (71). Finally, **TSSC4** gene is located in 11p15.5 locus, an important tumor-suppressor gene region which alterations are linked with the Beckwith–Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer (https://www.genecards.org/cgi-bin/carddisp.pl?gene=TSSC4).

To improve performance of ML, we used a recent data preprocessing/trimming technique termed floating-window projective separator (FloWPS). This method increases AUC for most of ML methods in most of the clinically annotated gene expression datasets investigated (26, 48, 49). FloWPS improves the classifier robustness by performing dynamic data trimming and selecting sample-specific sets of relevant genes to prevent extrapolation in the feature space (described in detail in Supplementary Text 1). It prevents extrapolation in the feature space by excluding the features that cause such extrapolation. Second, it selects only \( k \) nearest neighbors for

![FIGURE 1](https://www.frontiersin.org/) | The hierarchical clustering dendrogram of all experimental RNA sequencing profiles of the control and multiple myeloma samples. Gene expression data were used to calculate Euclidian distances between the samples. Color indicates the sample type. The lower scale indicates the number of uniquely mapped reads. QC denotes the quality control threshold of 2.5 million uniquely mapped reads.
the training dataset to build a ML model similarly to the kNN method (72) to avoid confusing interference from too distant points from the training dataset in the feature space.

We then built binary classifiers of MM response on PAD and VCD regimens using five ML methods: linear support vectors machine (SVM) (50, 73, 74), random forests (RF) (75), ridge regression (RR) (76), binomial naive Bayes (BNB) (77), and multi-layer perceptron (MLP) (52, 74, 78). We checked performance of these methods with and without FloWPS. Cross-validation of the results for every method was done using the leave-one-out approach to calculate quality metrics such as AUC, sensitivity and specificity. The results are shown in Figures 5, 6 depending on different values of B, a relative balance factor for false positive and false negative errors. For all ML methods, application of FloWPS increased quality of the classifiers built as reflected by AUC metric (Figures 5, 6). Taking together the three criteria of AUC, sensitivity (Sn) and specificity (Sp), the optimal solution was provided by the BNB method with FloWPS (AUC = 0.84) for the full cohort, and by MLP method with FloWPS (AUC = 0.89) for the VCD cohort.

**Comparison With Other Publicly Available Gene Expression Datasets With Known MM Response to Bortezomib-Containing Chemotherapy Regimens**

We found seven publicly available MM datasets containing gene expression profiles annotated by clinical responses to the different bortezomib containing treatment schemes (25, 27–29, 32) summarized here on Table 3. Among them, only two chemotherapy scheme (bortezomib + thalidomide + dexamethasone) and PAD are currently accepted by the NCCN guidelines (79). All those alternative datasets were obtained by using expression microarrays whereas RNA sequencing that can be considered gold standard of cancer transcriptomic analyses (80).
was used here for the first time to characterize PAD and VCD treatment efficiencies.

When processed in the same way as the current experimental dataset to apply different ML methods, 7–18 core marker genes distinguishing good and poor responders were obtained for these literature datasets (26). We found no intersections between the core marker genes corresponding to these and current experimental datasets (Table 4). Moreover, using the current experimental set of 8/10 core marker genes (for the full/VCD cohorts, respectively) couldn’t be used for building robust classifiers with the same repertoire of ML methods (data not shown). This can be due to differences in both gene expression interrogation methods, MM

---

**FIGURE 3** | Gene expression levels of genes ARPC2 (A), EIF4BP8 (B), KLHDC7B (C), OSR2 (D), RPL21P1 (E), SETP4 (F), TRIM9 (G), and TSSC4 (H) in the full cohorts of MM responders and poor responders to PAD/VCD therapy. For every gene, paired t-test p-values and AUC values are shown. Each dot on the graph represents single MM sample. Grey indicates good treatment responders, black—poor responders.
FIGURE 4 | Gene expression levels of genes ARPC2 (A), CDHR4 (B), EFCAB8 (C), EIF4BP8 (D), OSR2 (E), SETP4 (F), SLC25A6P3 (G), TOGARAM1 (H), TRIM9 (I), and TSSC4 (J) in the cohorts of MM responders and poor responders to VCD therapy. For every gene, paired t-test p-values and AUC values are shown. Each dot on the graph represents single MM sample. Grey indicates good treatment responders, black—poor responders.
TABLE 2 | Core marker genes for the current PAD/VCD MM dataset (full cohort/VCD cohort).

| Gene ID | Cohort | Regulation in responders/non-responders | Molecular function |
|---------|--------|----------------------------------------|-------------------|
| ARPC2   | Full, VCD | Up/down control of actin polymerization |                   |
| CDHR4   | VCD    | Down/up cell adhesion protein; sorting of heterogeneous cell types |                   |
| EFCAB8  | VCD    | Down/up Calcium ion binding             |                   |
| EIF4BP8 | VCD    | Down/up eukaryotic translation initiation factor 4B pseudogene 8 |                   |
| KHIQC7B | Full   | Down/up Kelch domain-containing protein 7B |                   |
| OSR2    | Full, VCD | Down/up transcription factor |                   |
| RPL21P1 | Full   | Down/up ribosomal protein L21 pseudogene 1 |                   |
| SEPT4   | Full, VCD | Down/up SET pseudogene 4 |                   |
| SLCA6P3 | VCD    | Down/up mitochondrial carrier; adenine nucleotide translocator, member 6 pseudogene 3 |                   |
| TGFAM1  | VCD    | Down/up microtubule binding             |                   |
| TRIM9   | Full, VCD | Down/up includes TRIM motif with three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region |                   |
| TSSC4   | Full, VCD | Down/up tumor suppressing subtransferable candidate 4 |                   |

1 Gene name according to HGNC nomenclature (63).
2 Up/downregulation of marker genes in the treatment responders and non-responders, accordingly.
3 Gene function according to GeneCards knowledgebase (64).

FIGURE 5 | Area under receiver-operator curve (AUC), sensitivity (Sn) and Specificity (Sp) for five ML methods (A) linear SVM, (B) RF, (C) RR, (D) BNB, (E) MLP during classification of response to PAD/VCD treatment of 53 MM patients (full cohort). Parameter B is false positive vs. false negative balance factor.
heterogeneity, and the composition of MM treatment schemes. Similarly, findings of Intergroupe Francophone du Myélome (IFM) suggest the absence of a robust gene signature associated with the treatment response (14, 81, 82).

However, for all the literature datasets investigated utilization of best ML methods enhanced by FloWPS using their own core biomarker genes resulted in high-quality classifiers with ROC AUC varying in the range 0.79–0.96 (Table 5). Interestingly, one of those previous MM datasets (25) for bortezomib monotherapy (best AUC = 0.8) was previously characterized as “inconvenient” for ML because other attempts to build a response classifier without using core marker gene approach and FloWPS were unsuccessful resulting in AUC <0.66 (83–87).

For ROC AUC metric, FloWPS enhancement was beneficial for all global ML methods such as SVM, RF, BNB, and MLP. Likewise, it increased the precision-recall AUC (AUPR) metric for global ML methods in most datasets (Table 5). This was also in line with the previous findings where it could improve accuracy and Matthews correlation coefficient metrics (48).

**Differentially Expressed Gene Analysis**

We performed the analysis for differentially expressed genes that distinguish responders from non-responders using the DESeq2 (51) method with the criteria \( \text{pAdjusted} <0.05, |\text{LFC}_2| >0.5 \) (Supplementary Figure 2). Interestingly, we found no marker role of bortezomib molecular target genes PSMB1 and PSMB5 for neither dataset, as reflected by AUC levels of less than 0.7 (Supplementary Figure 1).

Despite the lack of intersection between core marker genes that served for ML model creation, there were several differential genes that were regulated similarly among the good vs poor responders in the different datasets, and the intersection pattern was not random (Figure 7).

The intersections between differential genes for all datasets were analyzed using UpSetR method (88); Figure 7A. To assess randomness of differential genes in the MM datasets, we used the following test. Differential gene sets for all MM datasets can form \( 7 \times 8/2 = 28 \) pair intersections. For each of these paired intersections the number of observed intersected genes was calculated and compared with the random expectation model (Figure 7B). For random expectations, in each dataset we picked 1,000 times randomly the observed number of differential genes, and modeled all 28 possible intersections (Figure 7B).

The maximum similarities were observed between the datasets GSE68871 and GSE19784_1 (Jaccard coefficient \( J = 0.042 \)), GSE68871 and GSE19784_2 (\( J = 0.037 \)), GSE68871 and...
TABLE 3 | General characteristics of bortezomib chemotherapy response-annotated MM datasets.

| Reference | Dataset ID | Therapy | Experimental platform | Number N of cases (R vs NR) | Number of core marker genes |
|-----------|------------|---------|-----------------------|----------------------------|-----------------------------|
| Current study (full cohort) | Bortezomib, doxorubicin, dexamethasone (PAD) AND/OR Bortezomib, cyclophosphamide, dexamethasone (VCD) | RNA sequencing, Illumina HiSeq 3000 | 53 (28 R: complete response + very good partial response; 25 NR: partial response + minimal response) | 8 |
| Current_Study_VCD | Bortezomib, cyclophosphamide, dexamethasone (VCD) | RNA sequencing, Illumina HiSeq 3000 | 47 (24 R: complete response + very good partial response; 23 NR: partial response + minimal response) | 10 |
| (25) GSE9782 | Bortezomib monotherapy | Affymetrix Human Genome U133 Array | 169 (85 R: complete response + partial response; 84 NR: no change + progressive disease) | 18 |
| (29) GSE68871 | Bortezomib-thalidomide-dexamethasone | Affymetrix Human Genome U133 Plus 2.0 Array | 118 (69 R: complete, near-complete and very good partial responders; 49 NR: partial, minor and worse) | 12 |
| (27) GSE55145 | Bortezomib followed by ASCT | Affymetrix Human Genome U133 Plus 2.0 Array | 61 (33 R: complete, near-complete and very good partial responders; 28 R: partial, minor and worse) | 14 |
| (32, 41) GSE19784_1 | Bortezomib, doxorubicin, dexamethasone (PAD) | Affymetrix Human Genome U133 Plus 2.0 Array | 61 with ISS stage I [32 R, 29 NR (32)] | 7 |
| (32, 41) GSE19784_2 | Bortezomib, doxorubicin, dexamethasone (PAD) | Affymetrix Human Genome U133 Plus 2.0 Array | 51 with ISS stage II [33 R, 18 NR (32)] | 12 |
| (32, 41) GSE19784_3 | Bortezomib, doxorubicin, dexamethasone (PAD) | Affymetrix Human Genome U133 Plus 2.0 Array | 41 with ISS stage III [29 R, 12 NR (32)] | 11 |
| (32, 34) GSE2658 | Bortezomib, doxorubicin, dexamethasone (PAD) | Affymetrix Human Genome U133 Plus 2.0 Array | 208 [55 R, 153 NR (32)] | 16 |

GSE19784_4 (I = 0.030), and GSE68871 and GSE2658 (I = 0.028); Supplementary Table 5.

Interestingly, we found several common differential genes in the current experimental RNAseq and in the previous microarray datasets (Table 6). All these common differential genes were overexpressed in the good vs poor treatment responders. Among them, the fibroblast growth factor receptor 3 gene (FGFR3) was found three times, and the transcription factor MAF gene was detected twice. Other differential genes (IGHA2, IGHV1-69, GRB14) were detected once. Among them, GRB14 was found only for the full (PAD+VCD) dataset, but not in the reduced VCD dataset. Other abovementioned differential genes were shared for the PAD + VCD and VCD datasets.

TABLE 4 | Core marker genes identified for bortezomib chemotherapy response-annotated MM datasets; genes that are overexpressed in the treatment responders are marked by (+), downregulated in the responders by (−).

| Current study full cohort | Current study VCD cohort | GSE9782 | GSE68871 | GSE55145 | GSE19784_1 | GSE19784_2 | GSE19784_3 | GSE2658 |
|--------------------------|--------------------------|--------|----------|----------|-------------|-------------|-------------|---------|
| ARPC2 (+)                | ARPC2 (+)                | ABHD14A (-) | BORCS8 (-) | AKNA (-) | ACE2 (+) | DCDN1D2 (-) | ANKRD11 (-) | BCOR (+) |
| EIF4BP8 (-)              | EIF4BP8 (-)              | ATP2B4 (+) | BTG1 (-) | CATSPER3 (+) | C22orf24 (-) | GTF2A1L (-) | FAM132A (+) | CCND1 (-) |
| KLHCDC7B (-)             | KLHCDC7B (-)             | ATP5S (-) | CCND1 (-) | EMP3 (+) | FAM132A (-) | GRP124 (+) | HS3ST5 (+) | SCN9A (+) |
| OSR2 (-)                 | OSR2 (-)                 | ATP5SL (-) | CSTB (-) | MYH9 (-) | GTP2A1L (+) | HGIO (+) | FH (-) | SMARCA2 (+) |
| RPL21P1 (-)              | RPL21P1 (-)              | ATP6V0D1 (+) | CTCL (-) | NDRG2 (-) | PPP4R4 (+) | MEI1 (-) | KRT35 (-) | REM1 (+) |
| SET7P4 (-)               | SET7P4 (-)               | B2M (+) | GNAS1 AS1 (-) | NUCG2 (-) | RP11.680024.5 (-) | STK39 (-) | LINCO0031 (-) | MELI (-) |
| TRIM9 (-)                | TRIM9 (-)                | BCL2L11 (-) | ORAI1 (-) | PASK (-) | RAPGEF1 (+) | RBPS6 (+) | HSACS (+) | S100PBP (+) |
| TSSC4 (-)                | TSSC4 (-)                | C7orf26 (-) | PLOD3 (-) | RPRPBP (-) | TMEM131L (-) | RP5.1096D14.1 (-) | NOXO1 (-) | SHOC21 (+) |
|                        |                         | CONB1P1 (-) | SCNA9 (-) | SMARCA5 (-) | TMEM99 (-) | RP11.9600B2.9 (+) | REM1 (+) | SMC4 (+) |
|                        |                         | COX7C (-) | STK33 (-) | TRAF3 (-) | TRAF4 (-) | RP11.164P12.4 (-) | S100PBP (-) | UNC19C (+) |
TABLE 5 | Best ROC AUC and AUPR (precision-recall AUC) values obtained for good versus poor responder classifiers built using different ML methods without/with FloWPS for different MM annotated expression datasets.

| Dataset                        | SVM  | RF   | RR    | BNB   | MLP  |
|-------------------------------|------|------|-------|-------|------|
| Current study full ROC AUC    | 0.80/0.82 | 0.76/0.82 | 0.86/0.87 | 0.79/0.84 | 0.81/0.83 |
| Current study full AUPR       | 0.79/0.82 | 0.78/0.79 | 0.88/0.90 | 0.78/0.83 | 0.79/0.81 |
| Current study VCD ROC AUC     | 0.82/0.86 | 0.74/0.83 | 0.86/0.87 | 0.78/0.86 | 0.84/0.89 |
| Current study VCD AUPR        | 0.82/0.86 | 0.76/0.86 | 0.86/0.84 | 0.79/0.92 | 0.83/0.86 |
| GSE9782 ROC AUC               | 0.68/0.72 | 0.68/0.80 | 0.77/0.77 | 0.73/0.76 | 0.72/0.76 |
| GSE9782 AUPR                  | 0.65/0.70 | 0.70/0.80 | 0.77/0.77 | 0.69/0.76 | 0.69/0.74 |
| GSE568771 ROC AUC             | 0.68/0.77 | 0.73/0.83 | 0.78/0.77 | 0.74/0.84 | 0.70/0.80 |
| GSE668771 AUPR                | 0.64/0.76 | 0.73/0.83 | 0.79/0.77 | 0.71/0.80 | 0.69/0.76 |
| GSE55145 ROC AUC              | 0.78/0.82 | 0.77/0.90 | 0.87/0.84 | 0.82/0.87 | 0.80/0.85 |
| GSE55145 AUPR                 | 0.72/0.84 | 0.72/0.84 | 0.88/0.85 | 0.83/0.82 | 0.83/0.82 |
| GSE19784_1 ROC AUC            | 0.65/0.82 | 0.74/0.77 | 0.84/0.84 | 0.74/0.84 | 0.72/0.81 |
| GSE19784_1 AUPR               | 0.64/0.77 | 0.71/0.77 | 0.86/0.84 | 0.72/0.84 | 0.69/0.79 |
| GSE19784_2 ROC AUC            | 0.83/0.87 | 0.75/0.82 | 0.92/0.94 | 0.89/0.94 | 0.86/0.87 |
| GSE19784_2 AUPR               | 0.85/0.91 | 0.79/0.86 | 0.96/0.97 | 0.92/0.97 | 0.88/0.89 |
| GSE19784_3 ROC AUC            | 0.84/0.94 | 0.84/0.86 | 0.95/0.95 | 0.86/0.96 | 0.91/0.94 |
| GSE19784_3 AUPR               | 0.89/0.95 | 0.89/0.90 | 0.98/0.98 | 0.92/0.98 | 0.95/0.96 |
| GSE26558 ROC AUC              | 0.72/0.77 | 0.67/0.79 | 0.79/0.79 | 0.76/0.78 | 0.63/0.72 |
| GSE26558 AUPR                 | 0.45/0.56 | 0.51/0.61 | 0.58/0.61 | 0.49/0.54 | 0.42/0.48 |

Four out of these five differential genes (FGFR3, MAF, IGH2A, IGHV1-69) are associated with translocation of immunoglobulin locus on 1q432 region that frequently occurs in MM (89), which clearly connects our results with the MM biology. Differential genes IGH2A and IGHV1-69 are both located on the above 1q432 locus and encode for immunoglobulin heavy chain constant region alpha 2, and immunoglobulin heavy chain variable regions 1–69, respectively. To our knowledge, they were never associated before with bortezomib effectiveness in MM and in other tumors. We also found no known associations for GRB14 with MM.

Our results on FGFR3 are congruent with the previous findings. Fibroblast growth factor receptor 3 (FGFR3) is receptor tyrosine kinase which prevents apoptosis in MM cells and promotes adhesion to bone marrow stromal cells (90). It is overexpressed in ~20% of MM cases (91). High expression of FGFR3 was reported as the positive clinical response prognostic factor for bortezomib monotherapy (92), and for the bortezomib + thalidomide + dexamethasone (VTD) regimen (93). In parallel with FGFR3 activating mutations (94), it was also shown a factor mediating and positively correlating with bortezomib-related apoptosis in cultured MM (91) and lymphoma (95) cells. Interestingly, at the same time FGFR3 overexpression was reported as a negative factor for treatment with thalidomide, another targeted MM therapeutic (96).

However, for transcriptional factor MAF contradictory reports have been published that its expression is either positive (97), neutral (98–100) or negative (101) prognostic factor for response on bortezomib containing treatments. MAF is a transcriptional activator of many genes, including cyclinD2 and Integrin-β7 (102). Translocation of MAF into immunoglobulin locus is initiating oncogenic event in 5–10% of MM cases, and it was estimated to be up-regulated in 40–50% of all multiple myelomas (103, 104).

To further functionally characterize the differential gene sets, we performed Gene Ontology (GO) analysis (105), Supplementary Figure 3. We identified enrichment clusters only for four datasets investigated: for the current study, GSE9782, GSE19784_1, and GSE2658. Those clusters corresponded predominantly to the various immune cell-specific processes (Supplementary Figure 3).

We also considered 20 experimental MM cases treated with PAD regimen and found four differential genes between the good and poor responders (Supplementary Figure 2C), including gene SEZ6L2 which was common with the literature dataset GSE9782. We found no previous mentions of the association of this gene with MM.

Gene Expression Changes in MM After PAD/VCD Treatment

To our knowledge, MM gene expression profiles before and after relapse on PAD/VCD regimens had never been reported in the literature. For two MM patients included in this study, we were able to isolate CD138+ fraction of MM cells for the bone marrow biopsies taken after recurrence of the disease (Table 7). The patient 111 sequentially had four courses of first-line PAD and two courses of VCD chemotherapy regimens and showed partial response before relapse. In turn, the patient 115 also had four courses of first-line PAD and two courses of VCD chemotherapy regimens but demonstrated only minimal response before relapse (Supplementary Table 1).

We compared expressions of bortezomib targeted genes in those patient biosamples before and after PAD/VCD treatment (Table 7). Interestingly, genes for both molecular targets of bortezomib (PSMB1, PSMB5) were downregulated after PAD/VCD treatment in both patients. This can represent tumor adaptation to the chemotherapy regimens used. However, it should be mentioned that those genes couldn’t serve as the bortezomib response prognostic biomarkers in all datasets investigated here (Supplementary Figure 1).
FIGURE 7 | Intersection analysis for differentially expressed genes (DEG) distinguishing good and poor treatment responders in eight bortezomib MM datasets (A). Observed vs expected (under the hypothesis of random DEG distribution) numbers of intersection events in all possible pairwise comparisons (B).

TABLE 6 | Common differentially expressed genes (DEGs) in the current experimental dataset (full or VCD only cohorts) and in seven previously published MM datasets.

| Dataset            | GSE9782 | GSE88671 | GSE55145 | GSE19784_1 | GSE19784_2 | GSE19784_3 | GSE2658 |
|--------------------|---------|----------|----------|-------------|-------------|-------------|---------|
| Common DEGs with full cohort | IGH1 (+), MAF (+) | FGFR3 (+) | – | FGFR3 (+) | IGHV1-69 (+) | FGFR3 (+) | GRB14 (+), MAF (+) |
| Common DEGs with VCD cohort | IGH1 (+), MAF (+) | FGFR3 (+) | – | FGFR3 (+) | IGHV1-69 (+) | FGFR3 (+) | MAF (+) |

(+) marks genes overexpressed in the good treatment responders.

TABLE 7 | Normalized expression levels of bortezomib targeting genes in MM patients before and after PAD/VCD treatment.

| Patient ID | Best response status | Sample status | PSMB1 expression¹ | PSMB5 expression¹ |
|------------|----------------------|---------------|-------------------|-------------------|
| MM111      | Partial response     | Pretreatment  | 880,4             | 669,9             |
| MM111      | Relapse              | 553           | 669,9             | 483,5             |
| MM1115     | Minimal response     | Pretreatment  | 814               | 456,3             |
| MM1115     | Relapse              | 604,6         | 456,3             | 282,8             |

¹Normalized counts of gene-mapped RNA sequencing reads.
DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/ repositories and accession number(s) can be found in the article/Supplementary Material.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the ethical committees of the Sechenov Moscow First Medical University, of the Clinical Center Vitamed (Moscow), and of the National Research Center for Hematology (Moscow, Russia). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

NB, MSu, VS, AS, MN, NG, MSo, and AB contributed conception and design of the study. NG performed autopsies. MN, LM, and AS isolated and prepared blood tissue samples. MSu and XL performed molecular analyses. NB, MR, MSu, NG, MSo, AGu, AGa, VT, and AB analyzed the data. NB, MR, MSo, VS, and AB wrote the paper. All authors contributed to the article and approved the submitted version.

FUNDING

The study was supported by the Oncobox research program in oncology, by OmicsWay Corp., by Amazon and Microsoft Azure grants for cloud-based computational facilities, by Russian Foundation for Basic Research grant 19-29-01108 to (Moscow, Russia). The patients/participants provided their written informed consent to participate in this study.

REFERENCES

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet (2009) 374:324–39. doi: 10.1016/S0140-6736(09)60221-X
2. Wang H, Naghavi M, Allen C, Barber RM, Carter A, Casey DC, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (2016) 388:1459–544. doi: 10.1016/S0140-6736(16)31012-1
3. Vos T, Allen C, Arora M, Barber RM, Brown A, Carter A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (2016) 388:1545–602. doi: 10.1016/ S0140-6736(16)31678-6
4. Maples KT, Joseph NS, Harvey RD. Current developments in the combination therapy of relapsed/refractory multiple myeloma. Expert Rev Anticancer Ther (2020) 20:1021–35. doi: 10.1080/14737140.2020.1828071
5. Poh C, Keegan T, Rosenberg AS. Second primary malignancies in multiple myeloma: A review. Blood Rev (2021) 46:100757. doi: 10.1016/j.bler.2020.100757
6. Špíčka I, Klánová M. Multiple myeloma. Vnitr Lek (2013) 59:627–30.

7. Sonneveld P, Schmidt-Wolf IG, Van Der Holt B, El Jarari L, Bertsch U, Salvwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol (2012) 30:2946–55. doi: 10.1200/JCO.2011.39.6820
8. Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood (2012) 119:4375–82. doi: 10.1182/blood-2011-11-395749
9. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial. Leukemia (2009) 23:1337–41. doi: 10.1038/leu.2009.26
10. Jimenez Zepeda VH, Duggan P, Neri PE, Bahls NJ. Cyclophosphamide, Bortezomib and Dexamethasone (CyBORD) Is A Feasible and Active Regimen for Non-Transplant Eligible Multiple Myeloma Patients. Blood (2014) 124:5751–1. doi: 10.1182/blood.v124.21.5751.5751
11. Punke AP, Waddell JA, Solimando DA. Lenalidomide, bortezomb, and dexamethasone (RVD) regimen for multiple myeloma. Hosp Pharm (2017) 52:27–32. doi: 10.1310/hp5201-27
12. Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone—alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet (2017) 389:519–27. doi:10.1016/S0140-6736(16)31594-X

13. Voorhees PM, Kaufman JL, Laubach J, Borovow DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood (2020) 136:936–45. doi:10.1182/blood.2020005288

14. Moreau P, Aget-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, et al. Bortezomib plus dexamethasone versus lenalidomide, thalidomide and dexamethasone as induction treatment before autologous stem-cell transplantation in newly diagnosed multiple myeloma. Blood (2011) 118:5752–8. doi:10.1182/blood-2011-05-355081

15. Yimer H, Melear J, Faber E, Bensinger WI, Burke JM, Narang M, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol (2019) 185:492–502. doi:10.1111/bjh.15806

16. Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet (2020) 395:394–403. doi:10.1016/S0140-6736(19)32419-1

17. Barlogie B, Anaisse E, Van Rhee F, Haessler J, Holligk I, Pineda-Roman M, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3. Br J Haematol (2007) 138:176–85. doi:10.1111/j.1365-2141.2007.06399.x

18. Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med (2018) 378:518–28. doi:10.1056/NEJMoa1714678

19. Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide, thalidomide and dexamethasone as induction treatment before autologous stem-cell transplantation in newly diagnosed multiple myeloma. Lancet (2017) 389:7618. doi:10.1016/S0140-6736(16)31594-X

20. Tkachev V, Borovov C, Garazha A, Buzdin A, Borisov N. Flexible data trimming improves performance of global machine learning methods in omics- based personalized oncology. Int J Mol Sci (2020) 21(3):713. doi:10.3390/ijms21030713

21. Amin SB, Yip WK, Minville S, Broyal A, Li Y, Hanlon B, et al. Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. Leukemia (2014) 28:2229–34. doi:10.1038/leu.2014.140

22. Borisov N, Borovov C, Tkachev V, Garazha A, Buzdin A. Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments. BMC Med Genomics (2020) 13:111. doi:10.1186/s12920-020-00759-0

23. Terragna C, Remondini D, Martello M, Zamagni E, Pantani L, Patriarca F, et al. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). Oncotarget (2016) 7:9666–79. doi:10.18632/oncotarget.5718

24. Went M, Sud A, Speedy H, Sunter NJ, Forsti A, Law PJ, et al. Genetic correlation between multiple myeloma and chronic lymphocytic leukemia provides evidence for shared aetiology. Blood Cancer J (2018) 9:1. doi:10.1038/s41408-018-0162-8

25. Went M, Sud A, Forsti A, Halvorsen B-M, Weinhold N, Kimber S, et al. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun (2018) 9:3707. doi:10.1038/s41467-018-04989-w

26. Ubel S, Sonneveld P, van Beers EH, Broijl A, van Vliet MH, de Ridder J. Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects. Nat Commun (2018) 9:2943. doi:10.1038/s41467-018-05348-5

27. Hanamura I, Huang Y, Zhan F, Barlogie B, Shaughnessy J. Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leukemia (2006) 20:1288–90. doi:10.1038/sj.leu.2404233

28. Zhan F, Huang Y, Cola S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood (2006) 108:2020–8. doi:10.1182/blood-2005-11-031458

29. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Holligk I, et al. Gene expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2007) 109:692–700. doi:10.1182/blood-2006-07-037077

30. Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, et al. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood (2010) 115:61–70. doi:10.1182/blood-2009-03-210526

31. Qiang Y-W, Ye S, Huang Y, Chen Y, Van Rhee F, Epstein J, et al. MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma. BMC Cancer (2018) 18:724. doi:10.1186/s12885-018-4602-4

32. Papanikolaou X, Alapat D, Rosenthal A, Stein C, Epstein J, Owens R, et al. The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma. Leukemia (2015) 29:1713–20. doi:10.1038/leu.2015.65

33. Bam R, Ling W, Khan S, Pennisi A, Venkateshia SU, Li X, et al. Role of Bruton’s tyrosine kinase in myeloma cell migration and induction of bone disease. Am J Hematol (2013) 88:463–71. doi:10.1002/ajh.23433

34. Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood (2008) 112:4235–46. doi:10.1182/blood-2007-10-119123

35. Broyal A, Hose D, Lokhorst H, de Krijgsman TG, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood (2010) 116:2543–53. doi:10.1182/blood-2009-12-261032

36. Chattopadhyay S, Thomsen H, Yadav P, da Silva Filho MI, Weihinold N, Nöthen MM, et al. Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma. Commun Biol (2019) 2:89. doi:10.1038/s42003-019-0329-2

37. Meißner T, Seckinger A, Hemminki K, Bertsch UF, Forstner A, Haenel M, et al. Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells. BMC Med Genomics (2015) 8:855. doi:10.1186/s12920-015-0161-6

38. Mitchell JS, Li N, Weinhold N, Forsti A, Ali M, van Duin M, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun (2016) 7:12050. doi:10.1038/ncomms12050

39. Tazar O, Srimornuk P, Daye CR, Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol (2013) 65:157–70. doi:10.1111/j.2042-7158.2012.01567.x
60. Liu T, Cheng G, Kang X, Xi Y, Zhu Y, Wang K, et al. Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging. *Neuroradiology* (2018) 60:653. doi: 10.1007/s00234-018-1999-z

61. Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, et al. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifying Genes Related to Human Tumor Progression. *Int J Oncol* (2020) 13:909. doi: 10.3892/ijo.2019.4626

62. Beltran-Anaya FO, Romero-Górdoba S, Rebolbar-Vega R, Arrieta O, Bautista-Piña V, Domínguez-Reyes C, et al. Expression of long non-coding RNA ENSG00000226738 (LncKLIHCDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death. *Mol Oncol* (2019) 13:999–27. doi: 10.1002/1878-0261.12446

63. Zhang G, Fan E, Yue G, Zhong Q, Shuai Y, Wu M, et al. Five genes as a novel signature for predicting the prognosis of patients with laryngeal cancer. *J Cell Biochem* (2020) 121:3804–13. doi: 10.1002/jcb.29535

64. Zong L, Hattori N, Yoda Y, Yamashita S, Takehashi H, Tahashashi T, et al. Establishment of a DNA methylation marker to evaluate cancer cell fraction in gastric cancer. *Gastric Cancer* (2016) 19:361–9. doi: 10.1007/s10120-015-0475-2

65. Mishima C, Kaga N, Matsu S, Tani T, Naoi Y, Shimoda M, et al. Promoter methylation of TRIM9 as a marker for detection of circulating tumor DNA in breast cancer patients. *SpringerPlus* (2015) 4:635. doi: 10.1186/s40666-014-1423-7

66. Altman NS. An Introduction to Kernel and Nearest-Neighbor Nonparametric Regression. *Am Statist* (1992) 46:175–8. doi: 10.2307/2685209

67. Tikhonov AN, Arsenin VY. Solutions of ill-posed problems. Scripta series in Mathematics. Hoboken, NJ: John Wiley & Sons Inc (1977).

68. Beltra Á, Mora S, Rebollar-Vega R, Arrieta O, Magranes F, Charbonnel C, Gouraud W, Jézéquel P, et al. Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myelome. *JCO* (2008) 26:4798–805. doi: 10.1200/JCO.2007.13.8545

69. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, et al. Multiple Myeloma, Version 1.2013. *J Natl Compr Canc Netw* (2013) 11:11–7. doi: 10.6004/jnccn.2013.0004

70. Buzdulac, Sorokin M, Garabini A, Glauser A, Alechin A, Podubelskaya E, et al. RNA sequencing for research and diagnostics in clinical oncology. *Semin Cancer Biol* (2019) 60:311–23. doi: 10.1016/j.semcancer.2019.07.010

71. Decaux O, Lodé M, Magranes F, Charbonnel C, Gouraud W, Jézéquel P, et al. Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myelome. *JCO* (2008) 26:4798–805. doi: 10.1200/JCO.2007.13.8545

72. Harousseau J-L, Shaughnessy J, Richardson P. Multiple Myeloma. *Hematology* (2004) 2004:233–56. doi: 10.1182/ashedducation-2004.1.237

73. Turkı T, Wang JTL. Clinical intelligence: New machine learning techniques for predicting clinical drug response. *Comput Biol Med* (2019) 107:302–22. doi: 10.1016/j.compbiomed.2018.12.017

74. Turkı T, Wei Z. A link prediction approach to cancer drug sensitivity prediction. *BMC Syst Biol* (2017) 11(Suppl 5):94. doi: 10.1186/s12918-017-0463-8

75. Turkı T, Wei Z. Learning approaches to improve prediction of drug sensitivity in breast cancer patients. In: 2016 38th Annual International Conference of the IEEE Engineering In Medicine and Biology Society (EMBC). Orlando, FL, USA: IEEE. (2016) pp. 3314–20. doi: 10.1109/EMBC.2016.7914377

76. Turkı T, Wei Z, Wang JTL. Transfer Learning Approaches to Improve Drug Sensitivity Prediction in Multiple Myeloma Patients. *IEEE Access* (2017) 5:7381–93. doi: 10.1109/ACCESS.2017.2696523
Borisov et al. ML for Predicting Bortezomib Response

87. Turki T, Wei Z, Wang JTL. A transfer learning approach via proximate analysis and mean shift for cancer drug sensitivity prediction. J Bioinform Comput Biol (2018) 16:1840014. doi: 10.1142/S0219720018400140

88. Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics (2017) 33:2938–40. doi: 10.1093/bioinformatics/btx364

89. Chei M, Bergagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol (2013) 97:313–23. doi: 10.1007/s12185-013-1291-2

90. Bisping G, Wenning D, Kropff M, Gustavus D, Müller-Tidow C, Stelljes M, et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in 4:1:4 myeloma. Clin Cancer Res (2009) 15:520–31. doi: 10.1186/1078-0432.CCR-08-1612

91. Guan M, Zhu L, Somlo G, Hughes A, Zhou B, Yen Y. Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells. Anticancer Res (2009) 29:1–9.

92. Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol (2008) 140:625–34. doi: 10.1111/j.1365-2141.2007.06921.x

93. Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia (2008) 22:1419–27. doi: 10.1038/leu.2008.99

94. Otsuka M, Mizuki M, Fujita J, Kang S, Kanakura Y. Constitutively active FGFR3 with Lys650Glu mutation enhances bortezomib sensitivity in plasma cell malignancy. Anticancer Res (2011) 31:113–22.

95. Zheng W, Guan M, Zhu L, Cai Z, Chung V, Huang H, et al. Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells. Anticancer Res (2010) 30:1921–30.

96. Ho PJ, Brown RD, Spencer A, Jelfs M, Danhier D, Gibson J, et al. Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. Leuk Lymphoma (2012) 53:1728–34. doi: 10.3109/10428194.2012.664842

97. Inagaki A, Tajima E, Uramishi M, Totani H, Asao Y, Ogura H, et al. Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma. Leuk Res (2013) 37:1648–55. doi: 10.1016/j.leukres.2013.09.026

98. Wang Y, Li Q, Xing S, Zhang H, Li D. Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk (2019) 19:e455–50. doi: 10.1016/j.clml.2019.05.016

99. Weinhold N, Heuch CJ, Rosenthal A, Thanendrarajan S, Stein CK, Van Rhee F, et al. Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia (2016) 30:425–30. doi: 10.1038/leu.2015.309

100. Wei G, Wang L, Yang H, Han X, Zheng G, Zheng W, et al. Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma. Exp Hematol Oncol (2017) 6:16. doi: 10.1186/s40164-017-0076-3

101. Nair B, van Rhee F, Shaughnessy JD, Anaissie E, Szymonifka J, Hoering A, et al. Superior results of Total Therapy 3 (2003–33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood (2010) 115:4168–73. doi: 10.1182/blood-2009-11-255620

102. Neri P, Ben L, Azab AK, Brentnall M, Gratton K, Klimowicz AG, et al. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood (2011) 117:2502–13. doi: 10.1182/blood-2010-06-292243

103. Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood (2011) 117:2396–404. doi: 10.1182/blood-2010-04-278788

104. Herath NI, Rocques N, Garancher A, Eychène A, Pouponnot C. GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target. Blood Cancer J (2014) 4:e175. doi: 10.1038/bcj.2013.67

105. Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. OMICS (2012) 16:284–7. doi: 10.1089/omi.2011.0118

Conflict of Interest: The AG, VT and MS were employed by Omicsway Corp. and Oncobox Ltd. AB was employed by Omicsway Corp.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Borisov, Sergeeva, Sutsvota, Raevskii, Gajifullin, Mendeleeva, Gudkov, Nareiko, Garazha, Tkachev, Li, Sorokin, Sarin and Buzdin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.